Identification of a ras oncogene peptide that contains both CD4+ and CD8+ T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization

被引:31
作者
Bristol, JA
Orsini, C
Lindinger, P
Thalhamer, J
Abrams, SI
机构
[1] NCI, Tumor Immunol & Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
[2] Salzburg Univ, Inst Chem & Biochem, A-5020 Salzburg, Austria
关键词
mouse; CD4(+) and CD8(+) T cells; nested epitopes; peptides; ras oncogenes;
D O I
10.1006/cimm.2000.1712
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in ras proto oncogenes are commonly found in a diversity of malignancies and may encode unique, non-self epitopes for T cell-mediated antitumor activity. In a BALB/c (H-2(d)) murine model, we have identified a single peptide sequence derived from the ras oncogenes that contained both CD8(+) and CD4(+) T cell. epitopes in a nested configuration. This peptide reflected ras sequence 4-16, and contained the substitution of Gly to Val at position 12 {i.e., 4-16(Val12)}. Mice immunized with this 13-mer peptide induced a strong antigen (Ag)-specific CD4(+) proliferative response in vitro. In contrast, mice inoculated with the wild-type ras sequence failed to generate a peptide-specific T cell. response, Additionally, mice immunized with the ras 4-16(Val12) peptide concomitantly displayed an Ag-specific CD8(+) cytotoxic T lymphocyte (CTL) response, as determined by lysis of syngeneic tumor target cells incubated with the nominal 9-mer nested epitope peptide {i.e., 4-12(Val12)}, as well as lysis of tumor target cells expressing the corresponding ras codon 12 mutation, Analysis of the V alpha- and V beta -chains of the T cell receptor (TCR) expressed by these CTL revealed usage of the V alpha1 and V beta9 subunits, consistent with the TCR phenotype of anti-ras Val12 CTL lines produced by in vivo immunization with the nominal peptide epitope alone. Moreover, immunization with the nested epitope peptide, as compared to immunization with either the 9-mer CTL peptide alone or an admixture of the 9-mer CTL peptide with an overlapping 13-mer CD4(+) T cell helper peptide {i.e., 5-17(Val12)} lacking the class I N-terminus anchor site, enhanced the production of the CD8(+) T cell response. Finally, immunization with plasmid DNA encoding the ras 4-16(Val12) sequence led to the induction of both Ag-specific proliferative and cytotoxic responses. Overall, these results suggested that a single peptide immunogen containing nested mutant ras-specific CD4(+) and CD8(+) T cell epitopes: (1) can be processed in vivo to induce both subset-specific T lymphocyte responses; and (2) leads to the generation of a quantitatively enhanced CD8(+) CTL response, likely due to the intimate coexistence of CD4(+) help, which may have implications in peptide- or DNA-based immunotherapies. (C) 2000 Academic Press.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 40 条
[1]  
Abrams SI, 1996, SEMIN ONCOL, V23, P118
[2]   Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations [J].
Abrams, SI ;
Khleif, SN ;
Bergmann-Leitner, ES ;
Kantor, JA ;
Chung, Y ;
Hamilton, JM ;
Schlom, J .
CELLULAR IMMUNOLOGY, 1997, 182 (02) :137-151
[3]   Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4(+) and CD8(+)T cell responses [J].
Abrams, SI ;
Stanziale, SF ;
Lunin, SD ;
Zaremba, S ;
Schlom, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) :435-443
[4]   PEPTIDE-SPECIFIC ACTIVATION OF CYTOLYTIC CD4(+) T-LYMPHOCYTES AGAINST TUMOR-CELLS BEARING MUTATED EPITOPES OF K-RAS P21 [J].
ABRAMS, SI ;
DOBRZANSKI, MJ ;
WELLS, DT ;
STANZIALE, SE ;
ZAREMBA, S ;
MASUELLE, L ;
KANTOR, JA ;
SCHLOM, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2588-2597
[5]   Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence [J].
Ahlers, JD ;
Takeshita, T ;
Pendleton, CD ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10856-10861
[6]   Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections [J].
Berzofsky, JA ;
Ahlers, JD ;
Derby, MA ;
Pendleton, CD ;
Arichi, T ;
Belyakov, IM .
IMMUNOLOGICAL REVIEWS, 1999, 170 :151-172
[7]  
BOS JL, 1989, CANCER RES, V49, P4682
[8]  
Bristol JA, 1998, J IMMUNOL, V160, P2433
[9]   Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4+ and CD8+ T lymphocytes following in vivo adoptive transfer [J].
Bristol, JA ;
Schlom, J ;
Abrams, SI .
CELLULAR IMMUNOLOGY, 1999, 194 (01) :78-89
[10]  
CARRENO BM, 1992, J IMMUNOL, V148, P894